Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that management will participate in three upcoming investor events as outlined below.
The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York. Motif will be presenting at 2:10 pm on September 10 in the Louis XVI A room.
BioCentury’s 22nd Annual NewsMakers in the Biotech Industry conference on September 10, 2015 at the New York City Millennium Broadway Hotel & Conference Center. Motif will be presenting at 10:00 am in room 311.
Ladenburg Thalmann 1st Annual Healthcare Conference on September 29, 2015 at the Sofitel Hotel in New York. Motif will be presenting at 10:30 am in Track 6: the Madeleine Room.
Enquiries
Motif Bio plc
Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
[email protected]
MC Services AG (TRADE PR)
Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / John Treacey
Dominic Wilson
+44 (0) 207 533 7727
Northland Capital Partners (Broker)
Patrick Claridge
John Howes
+44 (0) 207 382 1100
Plumtree Capital Limited (Financial Advisor)
Stephen Austin
+44 (0) 207 183 2493
Yellow Jersey PR
Dominic Barretto
Philip Ranger
Fiona Walker
+44 (0) 7768 537 739
Notes to Editors
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.